Anavex Life Sciences Invited to Present at a Neuro & Ophthalmology Conference

Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference

Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study

Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum

Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP

Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 First Quarter Financial Results

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results

Building Global Momentum for Interventions in Alzheimer's Disease - a Lausanne VIII Workshop Panel

Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference

Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access

Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference

Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result

Anavex Life Sciences to Announce Fiscal 2021 3rd Quarter Financial Results on Thurs., Aug. 12, 2021